Wandercraft, a self-balancing robotic mobility systems company, has announced that it has secured $75 million as part of its Series D round.
The new funding will help propel Wandercraft into its next phase of growth: bringing Eve, the world’s first self-balancing personal exoskeleton, to market as early as 2026; expanding clinical adoption of its flagship rehabilitation system, Atalante X; and developing and deploying Calvin-40, its humanoid robot.
Matthieu Masselin, CEO and Co-founder of Wandercraft, said, "The momentum we’ve achieved over the past few years is extraordinary. We’ve expanded globally, launched pivotal clinical trials, readied the commercialization of Eve, our personal exoskeleton, and entered a landmark partnership with Renault. This funding allows us to continue our mission of transforming how people live, move, and work across rehabilitation, home environments, and soon on factory floors.”
The news comes off the back of Wandercraft’s announcement with Renault Group, whereby the car manufacturer now has a minority stake ownership and a strategic partnership with Wandercraft. The partnership brings Renault Group’s industrial expertise to scale up production of Wandercraft’s exoskeletons and industrial robots. Renault is Wandercraft’s first commercial partner and customer of Calvin-40, named for its development time of just 40 days.
Calvin-40 is an industrial-grade robot intended for physically demanding tasks and the first humanoid robot developed by a European company, Calvin-40's rapid development was made possible by using Wandercraft’s rapid development process and existing leading-edge robotics platform integrated with NVIDIA Isaac technologies, including the NVIDIA Isaac GR00T N1 foundation model and the NVIDIA Jetson edge AI platform.
Looking ahead, the Series D funding will accelerate:
- Commercial deployment of Eve, the personal exoskeleton, in home and outdoor environments.
- A new phase of growth and support for Atalante X.
- Industrial development and rollout of Calvin-40 and the broader Calvin humanoid family.
The news follows a period of major growth since the company raised its Series C round of $45 million, which fueled U.S. commercial expansion and helped drive a tenfold increase in revenues.
